January Insights Paper – Pharma Services
INTRODUCTION
Investors in Pharma Services M&A faced formidable challenges in 2023, marked by high interest rates, dwindling deal volumes and pricing disparities between buyers and sellers.
However, optimism is increasing in 2024 as updated valuation models gradually bridge pricing gaps amid a more stable interest rate trajectory. The upcoming UK general election this year may spur further deal activity in H1, as the sector aims to preempt any potential tax alterations.
Simultaneously, as the pharma industry grapples with rising complexities in drug development, there is an imperative to acquire specialized expertise and quicker time-to-market solutions . Certain players, particularly those within the Outsourced Pharma Services space, stand to benefit from these dynamics.
To learn more about the key M&A trends taking shape this year in the Pharma Services space, read our latest paper.
